Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab

Modern Rheumatology

Volumn 24, Issue 3, 2014, Pages 511-516

  Tsuru, Tomomi ^a   Terao, Kimio ^b   Murakami, Miho ^c,d,e   Matsutani, Takaji ^c   Suzaki, Midori ^a   Amamoto, Toshiaki ^a   Nakashima, Hitoshi ^f   Akiyama, Azusa ^g   Nishimoto, Norihiro ^c,d,e  

^a Internal Medicine Medical Co LTA PS Clinic   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^c WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^d TOKYO MEDICAL UNIVERSITY   (Japan)

^e Osaka Rheumatology Clinic   (Japan)

^f FUKUOKA UNIVERSITY   (Japan)

^g Chugai Clinical Research Center Co Ltd   (Japan)

Author keywords

Castleman's disease; Humoral immune response; Influenza vaccine; Rheumatoid arthritis; Tocilizumab

Indexed keywords

ANTIBODY; BUCILLAMINE; CORTICOSTEROID; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; INFLUENZA VACCINE; INTERLEUKIN 6; METHOTREXATE; PNEUMOCOCCUS VACCINE; PREDNISOLONE; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; DRUG FEVER; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEROTYPE; SINGLE DRUG DOSE; TREATMENT DURATION; VACCINATION; VIRUS STRAIN; ARTHRITIS, RHEUMATOID; GIANT LYMPH NODE HYPERPLASIA; IMMUNOLOGY; MIDDLE AGED;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; GIANT LYMPH NODE HYPERPLASIA; HUMANS; IMMUNITY, HUMORAL; INFLUENZA VACCINES; MALE; MIDDLE AGED; PNEUMOCOCCAL VACCINES; VACCINATION;

EID: 84900460391     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2013.843743     Document Type: Article

References (34)

1. Kishimoto T. Interleukin-6: From basic science to medicine-40 years in immunology. Annu Rev Immunol. 2005; 23: 1-21
2. Nishimoto N. Kishimoto T. Interleukin-6: From bench to bedside. N at Clin Pract Rheumatol. 2006; 2(11): 619-26
3. Hirano T. Yasukawa K. Harada H. Taga T. Watanabe Y. Matsuda T et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature. 1986; 324(6092): 73-6
4. Suematsu S. Matsuda T. Aozasa K. Akira S. Nakano N. Ohno S. et al. IgG1 plasmacytosis in interleukin-6 transgenic mice. Proc Natl Acad Sci USA. 1989; 86(19): 7547-51
5. Noma T. Mizuta T. Rosen A. Hirano T. Kishimoto T. Honjo T. Enhancement of the interleukin-2 receptor expression on T cells by multiple B-lymphotropic lymphokines. Immunol Lett. 1987; 15(3): 249-53
6. Okada M. Kitahara M. Kishimoto S. Matsuda T. Hirano T Kishimoto T. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J. Immunol. 1988; 141(5): 1543-9
7. Kopf M. Baumann H. Freeer G. Freudenberg M. Lamers M. Kishimoto T. et al. Impaired immune and acute phase responses in interleukin-6-defi cient mice. Nature. 1994; 368(6469): 339-42
8. Yoshizaki K. Matsuda T. Nishimoto N. Kuritani T. Taeho L Aozasa K. et al. Pathogenic signifi cance of interleukin-6 (IL-6/BSF-2) in Castleman s disease. Blood. 1989; 74(4): 1360-7
9. Mitsuyama K. Sasaki E. Toyonaga A. Ikeda H. Tsuruta O. Irie A et al. Colonic mucosal interleukin-6 in infl ammatory bowel disease. Digestion. 1991; 50(2): 104-11
10. D e Benedetti F. Martini A. I s systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease?. J Rheumatol. 1998; 25(2): 203-7
11. Nishimoto N. Interleukin-6 as a therapeutic target in candidate infl ammatory diseases. Clin Pharmacol Ther. 2010; 87(4): 483-7
12. Sato K. Tsuchiya M. Saldanha J. Koishihara Y. Ohsugi Y. Kishimoto T et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. 1993; 53(4): 851-6
13. Nishimoto N. Hashimoto J. Miyasaka N. Yamamoto K. Kawai S Takeuchi T. et al. Study of active controlled monotherapy used for rheumatoid arthritis an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefi t from an X-ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis. 2007; 66(9): 1162-7
14. Nishimoto N. Kanakura Y. Aozasa K. Johkoh T. Nakamura M. Nakano S et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman Disease. Blood. 2 005; 1 06(8): 2 627-3 2
15. Yokota S. Imagawa T. Mori M. Miyamae T. Aihara Y. Takei S et al. Effi cacy and safety of tocilizumab in patients with systemiconset juvenile idiopathic arthritis: Randomised double-blind placebo-controlled withdrawal phase III trial. Lancet. 2008; 371(9617) : 998-1006
16. Imagawa T. Yokota S. Mori M. Miyamae T. Takei S. Imanaka H. et al. Safety and effi cacy of tocilizumab an anti-IL-6-receptor monoclonal antibody in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol. 2012; 22(1): 109-15
17. I to H. Takazoe M. Fukuda Y. Hibi T. Kusugami K. Andoh A. e t a l. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn s disease. Gastroenterology. 2004; 126(4): 989-96
18. Nishimoto N. Ito K. Takagi N. Safety and effi cacy profi les of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: Meta-Analysis of six initial trials and fi ve long-Term extensions. Mod Rheumatol. 2010; 20(3): 222-32
19. Schiff M H Kremer J M Jahreis A. Vernon E. Isaacs J D van Vollenhoven RF. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther. 2011; 13(5): R141
20. Grijalva CG. Chen L. Delzell E. Baddley JW. Beukelman T Winthrop KL. et al. Initiation of tumor necrosis factor-Alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA. 2011; 306(21): 2331-9
21. Fujiwara H. Nishimoto N. Hamano Y. Asanuma N. Miki S Kasayama S et al. Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: Report of two cases. Mod Rheumatol. 2009; 19(1): 64-8
22. Arnett FC. Edworthy SM. Bloch DA. McShane DJ. Fries JF Cooper NS. et al. The American Rheumatism Association 1987 revised criteria for the classifi cation of rheumatoid arthritis. Arthritis Rheum. 1988; 31(3): 315-24
23. Infl uenza HA vaccine package insert (The research foundation for microbial disease of Osaka University
24. Pneumovax 23 (Pneumococcal vaccine polyvalent) package insert 7999825 (Merck &Co. inc. Whitehouse Station NJ USA
25. Committee for Proprietary Medicinal Products (CPMP) Concept paper on the revision of the CPMP/BWP note for guidance on harmonization of requirements for infl uenza vaccines 2001 CPMP/ EWP/1045/01
26. Palmer DF. ColemanMT Dowdle WR. Advanced laboratory techniques for infl uenza diagnosis. Public health service. US Department of Health Education and Welfare. Atlanta: Center for Disease Control; 1975
27. Recommendations of the Swedish National Board of Health and Welfare. Pneumococcal Vaccination. http://www.Sos.se/sosfs/1994 26/1994-26.htm.May 2002?
28. Shinoki T. Hara R. Kaneko U. Miyamae T. Imagawa T. Mori M Yokota S. Safety and response to infl uenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab. Mod Rheumatol. 2012; 22(6): 871-6
29. Mori S. Ueki Y. Hirakata N. Oribe M. Hidaka T. Oishi K. Impact of tocilizumab therapy on antibody response to infl uenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis. 2012; 71(12): 2006-10
30. Obaro SK. Henderson DC. Monteil M. Immunity to pneumococcal infections. Lancet. 1995; 345(894): 70-1
31. Go ES. Ballas ZK. Anti-pneumococcal antibody response in normal subjects: Meta-Analysis. J. Allergy Clin Immunol. 1996; 98(1): 205-15
32. CDC recommendations of the Advisory Committee on Immunization practices (ACIP). Prevention of pneumococcal Disease 1997/46 (RR-08); 1-24) http://www.cdc.gov/mmwr/pdf/rr/rr4608. pdf (Oct 2013
33. Cho Y. Basta S. Chen W. Bennink JR. Yewdell JW. Heat-Aggregated noninfectious infl uenza virus induces a more balanced CD8- -T-lymphocyte immunodominance hierarchy than infectious virus. J Virol. 2003; 77(8): 4679-84
34. Griffi oen AW. Sanders L. Rijkers GT. Zegers BJ. Cell bilology of B lymphocyte activation by polysaccharides. J. Infect Dis. 1992 ; 165(Suppl 1): S71-3